Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Belzutifan in Metastatic Renal Cell Carcinoma: NCT06234605 Clinical Landscape Report 2026
16 October 2026
NCT06234605 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Melanoma, Cutaneous Malignant: NCT06240143 Clinical Landscape Report 2026
16 October 2026
NCT06240143 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AT-1965 in Solid tumor: NCT06234098 Clinical Landscape Report 2026
16 October 2026
NCT06234098 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Ovarian Cancer: NCT06233942 Clinical Landscape Report 2026
16 October 2026
NCT06233942 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride in Granular Cell Tumor: NCT06239272 Clinical Landscape Report 2026
16 October 2026
NCT06239272 clinical landscape for Granular Cell Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JSI-1187 in Advanced Malignant Solid Neoplasm: NCT06239623 Clinical Landscape Report 2026
16 October 2026
NCT06239623 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
MDX-2001 in Endometrial Carcinoma: NCT06239194 Clinical Landscape Report 2026
16 October 2026
NCT06239194 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab govitecan-hziy in Erythema Multiforme: NCT06238921 Clinical Landscape Report 2026
16 October 2026
NCT06238921 clinical landscape for Erythema Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Luveltamab Tazevibulin in Ovarian mixed epithelial carcinoma: NCT06238687 Clinical Landscape Report 2026
16 October 2026
NCT06238687 clinical landscape for Ovarian mixed epithelial carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
KSQ-001 in Lung Cancer: NCT06237881 Clinical Landscape Report 2026
16 October 2026
NCT06237881 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Epcoritamab in Indolent B-Cell Non-Hodgkin Lymphoma: NCT06238648 Clinical Landscape Report 2026
16 October 2026
NCT06238648 clinical landscape for Indolent B-Cell Non-Hodgkin Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
LY-4101174 in Solid tumor: NCT06238479 Clinical Landscape Report 2026
16 October 2026
NCT06238479 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.